Lieselotte De Smet

Lieselotte De SmetContact info

Lieselotte De Smet
Laboratory of Pharmaceutical Technology
Harelbekestraat 72, 9000 Gent (Belgium)
Tel: +32 0)9 2648068


Title of Ph.D. research work:

Hyperthermic interperitoneal drug delivery of different paclitaxel formulations in animal models for the treatment of peritoneal carcinomatosis


Until recently people with peritoneal carcinomatosis were considered incurable and terminally ill. In cases of gastrointestinal and ovarian carcinoma, peritoneal carcinomatosis is an important cause of death. Intraperitoneal chemotherapy has been developed for the treatment of colorectal and ovarian carcinoma with peritoneal metastasis. The benefit of this treatment lies in the presence of the peritoneum-plasma barrier  which allows that a higher concentration of local chemotherapy can be administered.

 Taxans (paclitaxel and docetaxel) are very active against many of the gastrointestinal and ovarian carcinoma. The problem with taxans is that they have a very poor water solubility. This reduces the efficacy and leads to a limited tissue penetration. At the moment Taxol®, consisting of Cremophor EL® and ethanol to increase the water solubility, is the only formulation of paclitaxel on the market. The use of Taxol® is not without risk as Cremophor EL® can cause an allergic reaction.

For this reason,  al lot of research is conducted into alternatives without Cremophor EL®.  All of these different formulations were tested for intravenous application but not for intraperitoneal use.

The final purpose of the project is to compare the different formulations of paclitaxel in vivo on rats with intraperitoneal carcinomatosis of colorectal and ovarian origin.


paclitaxel, peritoneal carcinomatosis and intraperitoneal chemotherapy